Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02114333 · ClinicalTrials.gov registry record · Phase 1
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
A Phase 1 study of Herpes Zoster and Shingles, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT02114333 is a Phase 1 study of Herpes Zoster and Shingles that has completed, run by University of Colorado, Denver. The registered enrollment target is 160 participants, below the 2,163-participant average among 16 other Herpes Zoster trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02114333, a Phase 1 study of Herpes Zoster and Shingles, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the two vaccines that have been developed to prevent and/or lessen the effects of shingles. One vaccine is live (Zostavax, licensed by FDA) and the other, herpes zoster subunit (HZ/su), contains a piece of the shingles virus (not live) and an ingredient that may enhance the body's immune response to the vaccine, and is currently investigational. The vaccines are being compared to assess their ability to stimulated protection against shingles. The study will provide an opportunity to determine the safety profile of each vaccine in a single trial. The study will also look at the effect of age on the immune response to the two vaccines and on the persistence of these responses.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL HZ/su vaccine
- BIOLOGICAL Zostavax
Study Locations (1)
Colorado
- Pediatric Infectious Diseases and Clinical Trials, Universtiy of Colorado School of Medicine - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2014-05 |
| Est. Completion | 2020-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02114333
The ClinicalTrials.gov registry entry for NCT02114333 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,163-participant average among 16 other Herpes Zoster trials with a reported enrollment target (93% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Herpes Zoster appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02114333 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT02114333 about?
NCT02114333 is a clinical study titled "Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds". This study will compare the two vaccines that have been developed to prevent and/or lessen the effects of shingles. One vaccine is live (Zostavax, licensed by FDA) and the other, herpes zoster subunit (HZ/su), contains a piece of the shingles virus (not live) and an ingredient that may enhance the b...
What is the current status of trial NCT02114333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2014-05. Estimated completion is 2020-05.
What conditions does trial NCT02114333 study?
This clinical trial studies the following conditions: Herpes Zoster, Shingles.
What interventions are being tested in trial NCT02114333?
The interventions under investigation include: Placebo (BIOLOGICAL), HZ/su vaccine (BIOLOGICAL), Zostavax (BIOLOGICAL).
Who is sponsoring clinical trial NCT02114333?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02114333 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
COMPLETED · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.